Produção de anticorpos anti-lipoproteína de baixa densidade oxidada para uso em diagnóstico laboratorial de risco cardiovascular

Abstract

Inflammatory disorders are strongly associated with the condition of oxidative stress, and atherosclerosis is one of the most studied condition. Atherosclerosis is a disease of great world-wide importance due to the high mortality of decurrently clinical conditions of the illness. Studies have demonstrated that the modification of the LDL is an important factor in the development of the illness. Therefore, the determination of the plasma LDL-ox is essential not only to investigate its relevance for the atherosclerotic diseases, but also to contribute in the diagnosis of these illnesses. The oxidation of low-density lipoprotein (oxLDL) induces the formation of immunogenic epitopes in molecules. However, the role of these antibodies in the pathophysiology of atherosclerosis and their clinical significance remain undefined. Objective this study was produce antibodies anti-LDLox in the diagnosis of atherosclerotic diseases and evaluate the association between LDLox and complex LDLox/anti-LDLox in activation the regulatory activity of PDI interconnected to Nox2 in inflammatory macrophages. Protein disulfide isomerase is an ubiquitously expressed enzyme that catalyses the rearrangement of disulfide bonds in target proteins. Previous studies suggest that PDI, which is a chaperone involved in protein trafficking and translocates to the cell surface, may regulate the phagocytic NADPH oxidase complex (Nox2). LDLox and complex LDLox/ anti-LDLox-triggered superoxide anion release was correlated with the PDI reductase activity detected in macrophages, as determined by oxygen consumption and cleavage of a fluorescent probe, respectively. Assays with the known PDI inhibitors bacitracin and dithionitrobenzoic acid were performed to confirm their ability to decrease the macrophages respiratory burst.